In this article I cover the “Value on the Move” strategy using estimated growth and give you a list of stocks currently passing our screen based on the approach. Investors are engaged in the battle of ...

GARP – growth at a reasonable price – can present companies with strong growth potential that are not overpriced, as well as ...

Airbnb is undervalued relative to its earnings, growth trajectory, and market position, making it a compelling investment opportunity. Despite slower growth and macroeconomic headwinds, Airbnb retains ...

Zillow maintains a dominant market position, supported by strong network effects, innovative tech, and expanding mortgage and rental segments. Z's valuation appears rich versus sector peers, but its ...

In this article I present AAII’s Oberweis Octagon stock-picking strategy and give you a list of stocks that currently pass our screen based on the approach. The Oberweis Octagon strategy focuses on ...

Risk management and diversification are crucial elements of professional investment management. For many, including this author, also believe that a strategic emphasis on factor investing will add ...

Shares of Adobe (NASDAQ:ADBE) tumbled recently, thanks in part to the U.S. Department of Justice's plans to block its $20 billion acquisition of Figma. Despite this, I still view Adobe as a stock that ...

Susan Dziubinski: Hi. I’m Susan Dziubinski with Morningstar. Today, we’re taking a look at four growth stocks trading at reasonable prices from the life sciences industry. Morningstar thinks these ...

Cabernet sauvignon is one of the world’s most-widely grown grape varieties, yet people in this country associate it with Bordeaux and California. But it has found a foothold in South America, ...

Bitcoin (BTC) remains on track to near $50,000 around next year’s block subsidy halving event, longtime analyst Filbfilb says. In his latest interview with Cointelegraph, the co-founder of trading ...

"When drug companies won't sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less." That is the rationale announced by the Biden ...